Ehrlichiosis is a tickborne bacterial infection, caused by bacteria of the family Anaplasmataceae, genera Ehrlichia and Anaplasma. These obligate intracellular bacteria infect and kill white blood cells. The average reported annual incidence is 0.7 cases per million people.
The most common symptoms include headache, muscle aches, and fatigue. A rash may occur, but is uncommon. Ehrlichiosis can also blunt the immune system by suppressing production of TNF-alpha, which may lead to opportunistic infections such as candidiasis. Most of the signs and symptoms of ehrlichiosis can likely be ascribed to the immune dysregulation that it causes. Late in infection, however, production of this substance can be upregulated by 30 fold, which is likely responsible for the "toxic shock-like" syndrome seen in some severe cases of ehrlichiosis. Some cases can present with purpura and in one such case the organisms were present in such overwhelming numbers that in 1991 Dr. Aileen Marty of the AFIP was able to demonstrate the bacteria in human tissues using standard stains, and later proved that the organisms were indeed Ehrlichia using immunoperoxidase stains. Experiments in mouse models further supports this hypothesis, as mice lacking TNF-alpha I/II receptors are resistant to liver injury caused by ehrlichia infection. 3% of human monocytic ehrlichiosis cases result in death; however, these deaths occur "most commonly in immunosuppressed individuals who develop respiratory distress syndrome, hepatitis, or opportunistic nosocomial infections. The total duration of illness for HME and HGA is unknown. No chronic cases have been reported at this time.
Ehrlichiosis occurs essentially worldwide, and the frequency parallels the distribution of the appropriate tick vectors for the transmission of Ehrlichia bacteria and the mammalian hosts. Ehrlichia sennetsu causes a mononucleosis-like illness in Japan and Malaysia.
Doxycycline and minocycline are the medications of choice. For people allergic to antibiotics of the tetracycline class, rifampin is an alternative. Early clinical experience suggested that chloramphenicol may also be effective, however, in vitro susceptibility testing revealed resistance. The preferred drug for human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) is doxycycline. In contrast to RMSF, chloramphenicol is not effective in ehrlichiosis. Antibiotic treatment should begin as soon as the diagnosis is ascertained. Antipyretics may be necessary. The American Academy of Pediatrics recommends doxycycline as first-line therapy for severe/life threatening suspected or proven HGA and HME. Ordinarily, tetracyclines are not administered to children younger than 8 years; however, chloramphenicol is the alternative treatment option. Oral chloramphenicol is no longer available in the United States. Thus, the American Academy of Pediatrics recommends doxycycline because the benefits outweigh the risks. Several case reports have detailed successful treatment of mild, non–life-threatening anaplasmosis (not ehrlichiosis) with rifampin in patients in whom doxycycline was contraindicated (eg, allergy, pregnancy)